MedTrace Logo

Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis

NCT00004690 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES: I. Compare the safety and efficacy of monolaurin cream versus a placebo vehicle cream in suppressing the signs of nonbullous congenital ichthyosiform erythroderma.

II. Assess the incidence of posttreatment rebound or recrudescence in patients with congenital ichthyosis.

III. Evaluate the long term safety of monolaurin cream with whole body application in these patients.

Conditions

  • Ichthyosis

Interventions

DRUG

monolaurin cream

Sponsors & Collaborators

  • Cellegy Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Carl R. Thornfeldt · Cellegy Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-09-30
Completion
1998-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004690 on ClinicalTrials.gov